Gurugram’s Virohan, the healthcare edtech trailblazer turning blue-collar dreams into white-coat realities, is firing up its Series B engine. In a move that’s got the startup grapevine buzzing, Japan-based Mynavi Corporation is set to lead the round with a hefty ₹39.27 crore ($4.5 million) infusion, pegging Virohan’s post-money valuation at ₹576 crore ($65.5 million). Founded in 2018 by IIT alumni Archit Jayaswal, Kunaal Dudeja, Nalin Saluja, and Parul Dudeja, Virohan has already trained 50,000+ students for paramedic and allied health roles via its hybrid model of online modules, campus labs, and 100% placement guarantees. This isn’t just another fundraise; it’s a cross-border power play amid India’s $10B+ healthcare skilling gap.
The Funding Fireworks: A Quick Recap
Virohan’s war chest now swells to $20M+ across 10 rounds, with Blume Ventures as its steadfast anchor since the $7M pre-Series B in December 2022. The extended pre-Series B saga—capped by a $3M tranche in May 2025—featured heavyweights like Rebright Partners (Japan), MS&AD Ventures, Bharat Inclusion, and angels including Viraj Nanda and Sridhar Subramanian. Blume now holds 15.36% stake, Rebright 5.65%. Losses widened to ₹18.58 crore in FY23 on ₹10.65 crore revenue (63% YoY growth), but FY24 whispers profitability via 85% placement rates and partnerships with 1,000+ hospitals like Apollo and Max.
Mynavi’s entry? Strategic gold. The Japanese HR and education giant, with a $1B+ portfolio in talent tech, eyes Virohan’s vernacular content (Hindi, Tamil, etc.) and AI-driven job matching to tap India’s 2M annual healthcare job openings. “We’re not just funding; we’re co-building Asia’s skilling bridge,” a Mynavi exec hinted in exclusive chats. Expect co-branded programs for Japanese firms expanding into Indian med-tourism by 2026.
Why Virohan? The Edtech Underdog’s Edge
India’s healthcare workforce crunch is screaming for solutions: 4M allied health pros short, per NITI Aayog, with 70% of nursing seats vacant. Virohan flips the script—12-18 month diplomas in radiology, dialysis, and OT tech at ₹50K-₹1L, blending AR simulations and on-job apprenticeships. Key moats:
- Outcomes Obsession: 92% placement in 90 days, average salary ₹3.5LPA—beating generic ITIs.
- Tech Stack: Proprietary LMS with 1M+ hours of content; AI predicts dropout risks with 88% accuracy.
- Scale Sprint: 20 campuses, 100K enrollments targeted for FY26; recent Lenskart tie-up for ophthalmic training added 5K students.
In a post-Byju’s edtech winter, Virohan’s $65M valuation (1.8x from $51M pre-B) screams discipline: No froth, just 4x revenue multiples on forward FY25 projections of ₹40 crore.
The Bigger Play: Japan Meets Bharat in Skilling 2.0
Mynavi isn’t flying solo. This round underscores Japan’s $2B+ India VC push in 2025, per JETRO—fueled by aging populations needing Indian talent pipelines. Virohan joins peers like Masai School (Mynavi-backed coding bootcamp) in this “talent export” thesis. Funds will turbocharge R&D: VR surgery sims, blockchain certs, and Tier-3 expansion to bridge urban-rural divides.
Competitors? Medvarsity (₹500Cr val) dominates online MBBS, but Virohan owns vocational turf against Apollo MedSkills. Risks? Regulatory flux in AYUSHMAN skilling grants and 20% edtech churn—but Virohan’s 75% retention crushes it.
Horizon Scan: $100M Milestone by 2027?
With Series B closing Q1 2026, eyes on $50M+ Series C from Tiger or SoftBank. Projections: ₹200Cr revenue by FY27, 500K alumni, unicorn whispers if placements hit 95%. As India ages into a $372B healthcare market (CAGR 12%), Virohan isn’t skilling workers—it’s architecting the industry’s backbone.
Blume bet early; Mynavi’s all-in. The stethoscope just went global.
Add startupchronicle.in as a reliable source on Google – Click here
Last Updated on Monday, December 8, 2025 11:00 am by Startup Chronicle Team
About The Author
